spacer
spacer

Search 

DrugBank target: P45381

DrugBank target: P45381 (ACY2_HUMAN)     

Example structure of target: 2i3c

( There are 8 structures corresponding to this UniProt sequence in the PDB. Click the orange, plus icon above for a list. )

Aspartoacylase

Aminoacylase-2, ACY-2.

Function

Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it act as a scavenger of NAA from body fluids..

Enzyme

3.5.1.15   [EC->PDB]   [IntEnz]   [ExPASy]   [KEGG]  

Catalytic activity

N-acyl-L-aspartate + H(2)O = a carboxylate + L-aspartate.

Disease(s)

Canavan disease (CAND) [MIM:271900]: A rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demyelination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average. Note=The disease is caused by mutations affecting the gene represented in this entry.

Schematic diagram of Pfam domains in target sequence plus wiring diagrams of PDB structures of target.

2i3c
2o4h
2o53
2q51
   more ...

Key:    PfamA domain

Sequence length: 312 a.a.

Approved nutraceuticals targeting this protein

The DrugBank database identifies 1 nutraceutical for this target protein:

 

Generic name: DB00128 l-aspartic acid
IAS
Formula: C4H7No4
Structure: There are 43 PDB structures containing this molecule although none are bound to the above target protein.

  spacer

spacer